{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:14:57Z","timestamp":1790072097581,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.msard.2022.103907","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T17:36:35Z","timestamp":1653240995000},"page":"103907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: A single-center tertiary care cohort"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-6450","authenticated-orcid":false,"given":"Nanthaya","family":"Tisavipat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikaew","family":"Lapanakoakiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimkamon","family":"Siengwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthapon","family":"Rattanathamsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiraporn","family":"Jitprapaikulsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naraporn","family":"Prayoonwiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-697X","authenticated-orcid":false,"given":"Sasitorn","family":"Siritho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103907_bib0001","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.103907_bib0002","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","article-title":"Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica","volume":"126","author":"Ratelade","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2022.103907_bib0003","article-title":"Asian and African\/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence","volume":"53","author":"Soares-dos-Reis","year":"2021","journal-title":"Multiple Sclerosis Rel Disord."},{"key":"10.1016\/j.msard.2022.103907_bib0004","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2022.103907_bib0006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.msard.2022.103907_bib0007","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0008","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol., Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2022.103907_bib0009","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02083-1","article-title":"The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt","volume":"21","author":"Kishk","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2022.103907_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0011","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2022.103907_bib0012","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0013","first-page":"827","article-title":"AQP4 antibody\u2013positive Thai cases","volume":"77","author":"Siritho","year":"2011","journal-title":"Clin. Features Diagnostic Prob."},{"key":"10.1016\/j.msard.2022.103907_bib0014","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","article-title":"Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen","volume":"291","author":"Jarius","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.103907_bib0015","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.103907_bib0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.msard.2016.06.006","article-title":"How long does it take to diagnose patients with neuromyelitis optica (NMO) using the 2006 diagnostic criteria?","volume":"9","author":"Tengsirikomol","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103907_bib0017","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0018","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple sclerosis severity score","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0019","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103907_bib0020","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0022","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.103907_bib0023","article-title":"Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder","author":"Liu","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.msard.2022.103907_bib0024","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol. - Neuroimmunol. Neuroinflammat."},{"key":"10.1016\/j.msard.2022.103907_bib0025","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00396","article-title":"Value of area postrema syndrome in differentiating adults with AQP4 vs. MOG antibodies","volume":"11","author":"Hyun","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2022.103907_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2022.103907_bib0028","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2017.07.013","article-title":"Clinical characteristics and long-term visual outcome of optic neuritis in neuromyelitis optica spectrum disorder: A comparison between Thai and American-Caucasian cohorts","volume":"17","author":"Vanikieti","year":"2017","journal-title":"Multip. Scleros. Rel. Disord."},{"key":"10.1016\/j.msard.2022.103907_bib0029","first-page":"206","article-title":"Clinical Course and treatment response of neuromyelitis optica spectrum disease: an 8-year experience","volume":"8","author":"Lin","year":"2019","journal-title":"The Asia-Pacific J. Ophthalmol."},{"key":"10.1016\/j.msard.2022.103907_bib0030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.103907_bib0031","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders \u2014 from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.103907_bib0032","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflammat."},{"key":"10.1016\/j.msard.2022.103907_bib0033","article-title":"The 2015 IPND criteria increases the yield in diagnosis of neuromyelitis optica spectrum disorder in Thai patients compared to the 2006 diagnostic criteria","volume":"43","author":"Rattanathamsakul","year":"2020","journal-title":"Multip. Scleros. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103907_bib0034","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol. - Neuroimmunol. Neuroinflammat."},{"key":"10.1016\/j.msard.2022.103907_bib0035","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.2147\/OPTH.S285443","article-title":"Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-related optic neuritis in affected eyes","volume":"14","author":"Thongmee","year":"2020","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"10.1016\/j.msard.2022.103907_bib0036","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.103907_bib0037","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.msard.2018.07.003","article-title":"Multiple sclerosis and neuromyelitis optica spectrum disorders in Malaysia: A comparison in different ethnic groups","volume":"25","author":"Viswanathan","year":"2018","journal-title":"Multip. Scleros. Rel. Disord."},{"key":"10.1016\/j.msard.2022.103907_bib0038","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ncn3.12480","article-title":"Central nervous system demyelinating diseases in Hong Kong","volume":"9","author":"Li","year":"2021","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.msard.2022.103907_bib0039","article-title":"Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges","author":"Liu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2022.103907_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00160","article-title":"Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients","volume":"9","author":"Cangemi","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.msard.2022.103907_bib0041","doi-asserted-by":"crossref","first-page":"16727","DOI":"10.1038\/s41598-020-73882-8","article-title":"Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"10","author":"Songwisit","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2022.103907_bib0042","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/WNL.46.6.1607","article-title":"Risk of cancer from azathioprine therapy in multiple sclerosis","volume":"46","author":"Confavreux","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103907_bib0043","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"10.1016\/j.msard.2022.103907_bib0044","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/acn3.51404","article-title":"Mortality of neuromyelitis optica spectrum disorders in a Chinese population","volume":"8","author":"Du","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2022.103907_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Multip. Scleros. Rel. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:29Z","timestamp":1761901229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822004187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":45,"alternative-id":["S2211034822004187"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103907","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: A single-center tertiary care cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103907"}}